RxSight, Inc. is a commercial-stage medical technology company that was incorporated in California in 1997 under the name Calhoun Vision, Inc. and changed its name to RxSight, Inc. in October 2016. The company reincorporated in Delaware in July 2021 and maintains its principal executive offices in Aliso Viejo, California. RxSight focuses on delivering customized vision outcomes to patients after cataract surgery through its proprietary RxSight Light Adjustable Lens system.…
RxSight, Inc. is a commercial-stage medical technology company that was incorporated in California in 1997 under the name Calhoun Vision, Inc. and changed its name to RxSight, Inc. in October 2016. The company reincorporated in Delaware in July 2021 and maintains its principal executive offices in Aliso Viejo, California. RxSight focuses on delivering customized vision outcomes to patients after cataract surgery through its proprietary RxSight Light Adjustable Lens system. The system consists of a photosensitive intraocular lens known as the Light Adjustable Lens and a light delivery device called the Light Delivery Device that together enable postoperative adjustments to the lens power. Conventional premium intraocular lenses require patients to select their visual priorities before surgery and accept the optical trade offs inherent in those choices. Surgeons must rely on a series of preoperative measurements and predictive formulae to determine the appropriate lens power. If the selected power is not optimal the patient may experience less than ideal results that could require a subsequent corneal refractive procedure or other corrective measures to achieve intended vision targets. In contrast with the RxSight system the surgeon implants the Light Adjustable Lens as in any other cataract procedure determines refractive error with patient input several weeks following surgery and then uses the Light Delivery Device to modify the lens with the precise visual correction needed to achieve the patient’s desired vision outcomes. RxSight believes this approach eliminates the high stakes preoperative guesswork common to competitive premium intraocular lenses and allows patients to iterate their final vision characteristics with customized post surgical adjustments. The company operates in the premium intraocular lens segment of the ophthalmic medical device industry.
RxSight generates revenue principally from the sale of its Light Adjustable Lens implants and its Light Delivery Devices to eye care providers. The company follows a razor and razor blade business model in which it sells the Light Delivery Device as capital equipment and derives recurring revenue from the repeated use of Light Adjustable Lenses in cataract procedures. In the United States the premium cataract surgery market accounted for approximately twenty one percent of all cataract procedures in 2025 and generated about eight hundred sixty million dollars in revenue. The market is projected to grow at an eight percent compound annual growth rate through 2030. Globally about thirty three million cataract surgeries were performed in 2025 with five point two million occurring in the United States. As of December 31 2025 RxSight had an installed base of one thousand one hundred thirty four Light Delivery Devices in ophthalmology practices. Since its inception the company reports that surgeons have implanted approximately three hundred thousand Light Adjustable Lenses. The average practice using the RxSight system implants about eleven Light Adjustable Lenses per month based on internal surveys. A typical Light Delivery Device has a payback period of approximately six months for the purchasing practice after which the device continues to contribute to practice profitability. RxSight maintains a direct sales organization comprised of Light Delivery Device sales personnel Light Adjustable Lens account managers clinical specialists field service engineers and marketing staff to support its commercial efforts. The company also provides training onboarding and ongoing education to help practices succeed with the technology and to increase utilization of the lens implants.
RxSight holds a niche position in the premium cataract surgery market as the only provider of an adjustable intraocular lens that has received approval from the U. S. Food and Drug Administration. Its primary competitors in the United States premium intraocular lens market are large established companies such as Alcon and Johnson & Johnson which together account for a substantial share of the market with fixed power lens offerings. The company’s competitive advantage derives from its ability to modify lens power after implantation which allows surgeons to correct residual refractive error and to tailor vision to patient preferences without requiring a secondary surgical procedure. Clinical data show that approximately seventy percent of Light Adjustable Lens patients achieved twenty twenty or better uncorrected distance visual acuity without glasses in the pivotal study that supported FDA approval. In addition Light Adjustable Lens patients experience low rates of glare and halos compared with multifocal and extended depth of focus lenses which are associated with higher incidence of these side effects. The system also enables patients to preview and compare possible vision outcomes through up to three postoperative light treatments before selecting a final refractive correction. RxSight has obtained regulatory clearance for its RxSight system in the United States Europe Canada Mexico Singapore Australia and South Korea and has begun sales in select foreign jurisdictions where permitted. The company continues to invest in research and development to enhance clinical outcomes improve patient experience expand indications reduce manufacturing costs and manage the product lifecycle. Research and development expenses were thirty eight point five million dollars for the year ended December 31 2025 thirty four point four million dollars for the year ended December 31 2024 and twenty nine point one million dollars for the year ended December 31 2023. The company’s patent portfolio covers various aspects of the Light Adjustable Lens the Light Delivery Device the lens adjustment procedure and related accessories with individual patents estimated to expire between 2026 and 2045.
RxSight serves cataract surgeons who perform premium intraocular lens procedures in the United States and in select international markets. The company focuses its commercial efforts on approximately three thousand five hundred to four thousand U. S. cataract surgeons that carry out about sixty percent of all premium intraocular lens procedures in the country. Its products are sold to ambulatory surgical centers and hospitals that acquire the Light Adjustable Lens and Light Delivery Device for use in their surgical suites. Outside the United States RxSight has regulatory approval in Europe Canada Mexico Singapore Australia and South Korea and reports having begun sales in certain foreign jurisdictions where allowed. The company indicates that it has established an installed base of over one thousand Light Delivery Devices in ophthalmology practices and that the cumulative number of Light Adjustable Lens implants since inception approaches three hundred thousand. As of December 31 2025 the company employed four hundred sixty one full time employees none of whom are represented by a labor union or covered under a collective bargaining agreement. RxSight manufactures assembles tests and ships its Light Adjustable Lens and Light Delivery Device from a campus of five facilities in Aliso Viejo California that together comprise approximately one hundred fifty thousand total square feet. The company is registered with the FDA as a medical device manufacturer and is licensed by the State of California to manufacture and distribute its medical devices. RxSight has received International Organization for Standardization 13485 certification for its quality management system and maintains certification under the Medical Device Single Audit Program covering the jurisdictions of the United States Canada Japan Brazil and Australia.
Sector:HealthcareSector rationaleRxSight designs and manufactures medical devices, specifically the Light Adjustable Lens and the Light Delivery Device, used in cataract surgeries. Its revenue is derived from selling these medical implants and capital equipment to eye care providers, hospitals, and ambulatory surgical centers, which fits squarely within the Medical Devices industry of the Healthcare sector.Industry:Medical DevicesHealthcarePrimaryRxSight designs and manufactures therapeutic medical devices, specifically the Light Adjustable Lens (an intraocular implant) and the Light Delivery Device used for postoperative adjustments. The company generates revenue from the sale of these surgical devices to eye care providers, hospitals, and ambulatory surgical centers.Classified using BQ-MICSCIK: 0001111485
Investment Thesis
▲ Bull case
RxSight's core Light Adjustable Lens (LAL) technology demonstrates enduring clinical and economic value, with nearly 80% of ophthalmologists and optometrists indicating they would choose the LAL for themselves or a loved one, reflecting deep physician confidence in its ability to deliver superior, customized visual outcomes. This high level of endorsement, reinforced by the "I Trust It With My Own Eyes" campaign featuring real doctor testimonials, suggests strong underlying demand that is not fully captured in current utilization rates, particularly as reengagement programs begin to show early signs of impact in stabilized LAL volumes over three consecutive quarters. The company's focus on refining clinical outcome reviews, targeted IOL counseling, and in-person workflow support is designed to unlock latent demand from its large installed base of 1,154 LDD units and approximately 2,500 surgeons, positioning utilization growth as a key near-term catalyst that could drive LAL volumes above management's conservative low single-digit guidance for 2026.
International expansion, while currently modest in revenue contribution, represents a significant structural growth opportunity beginning in 2027 and beyond, supported by recent regulatory approvals in New Zealand, Australia, Europe, Singapore, and Korea. Management explicitly noted that international traction follows a predictable pattern seen in prior premium IOL launches, with early adoption in major European countries, Korea, and Australia—markets where RxSight is now establishing commercial footholds. The deliberate, infrastructure-focused approach aims to build durable relationships with leading surgeons and establish clinical and operational foundations, which, though not yet material to 2026 revenue, sets the stage for meaningful international revenue acceleration starting in 2027, contingent on successful PMA supplement processes and localized commercial execution.
Planned technical innovations aimed at streamlining LAL workflow—such as reducing the number of required LDD treatments, simplifying clinical workup for post-op adjustments, and extending the range of correction—are expected to reduce adoption friction for both clinicians and patients. These advancements, currently undergoing the PMA supplement process as a Class III device, are not yet reflected in near-term guidance but could meaningfully enhance procedural efficiency and patient satisfaction, thereby increasing LAL utilization per implanted lens and expanding the addressable market beyond current cataract surgery indications. Given the premium IOL segment's projected growth to 30%-40% of the cataract surgery market over time, as referenced by a major competitor, these innovations position RxSight to capture disproportionate share in a high-value, growing segment where its adjustability technology offers a differentiated clinical advantage over fixed premium IOLs.
Despite an 18% year-over-year revenue decline driven by deliberate pacing in LDD placements, the company maintained its full-year 2026 revenue guidance of $120 million to $135 million, indicating confidence in sequential improvement throughout the year as year-over-year comparisons ease and reengagement programs scale. Gross margin expansion to 76.1% in Q1—up from 74.8%—reflects a favorable shift toward higher-margin LAL revenue (88% of sales), with the anticipated step-down to 70%-72% for the full year attributed solely to the flow-through of higher-cost 2025 inventory, a temporary headwind expected to normalize as production absorption improves. This inventory-related margin pressure is not indicative of underlying business weakness but rather a transitional factor that will dissipate, allowing gross margin to potentially exceed current guidance ranges in subsequent years as cost structures stabilize and LAL volume growth resumes.
RxSight's core Light Adjustable Lens (LAL) technology demonstrates enduring clinical and economic value, with nearly 80% of ophthalmologists and optometrists indicating they would choose the LAL for themselves or a loved one, reflecting deep physician confidence in its ability to deliver superior, customized visual outcomes. This high level of endorsement, reinforced by the "I Trust It With My Own Eyes" campaign featuring real doctor testimonials, suggests strong underlying demand that is not fully captured in current utilization rates, particularly as reengagement programs begin to show early signs of impact in stabilized LAL volumes over three consecutive quarters. The company's focus on refining clinical outcome reviews, targeted IOL counseling, and in-person workflow support is designed to unlock latent demand from its large installed base of 1,154 LDD units and approximately 2,500 surgeons, positioning utilization growth as a key near-term catalyst that could drive LAL volumes above management's conservative low single-digit guidance for 2026.
International expansion, while currently modest in revenue contribution, represents a significant structural growth opportunity beginning in 2027 and beyond, supported by recent regulatory approvals in New Zealand, Australia, Europe, Singapore, and Korea. Management explicitly noted that international traction follows a predictable pattern seen in prior premium IOL launches, with early adoption in major European countries, Korea, and Australia—markets where RxSight is now establishing commercial footholds. The deliberate, infrastructure-focused approach aims to build durable relationships with leading surgeons and establish clinical and operational foundations, which, though not yet material to 2026 revenue, sets the stage for meaningful international revenue acceleration starting in 2027, contingent on successful PMA supplement processes and localized commercial execution.
Planned technical innovations aimed at streamlining LAL workflow—such as reducing the number of required LDD treatments, simplifying clinical workup for post-op adjustments, and extending the range of correction—are expected to reduce adoption friction for both clinicians and patients. These advancements, currently undergoing the PMA supplement process as a Class III device, are not yet reflected in near-term guidance but could meaningfully enhance procedural efficiency and patient satisfaction, thereby increasing LAL utilization per implanted lens and expanding the addressable market beyond current cataract surgery indications. Given the premium IOL segment's projected growth to 30%-40% of the cataract surgery market over time, as referenced by a major competitor, these innovations position RxSight to capture disproportionate share in a high-value, growing segment where its adjustability technology offers a differentiated clinical advantage over fixed premium IOLs.
Despite an 18% year-over-year revenue decline driven by deliberate pacing in LDD placements, the company maintained its full-year 2026 revenue guidance of $120 million to $135 million, indicating confidence in sequential improvement throughout the year as year-over-year comparisons ease and reengagement programs scale. Gross margin expansion to 76.1% in Q1—up from 74.8%—reflects a favorable shift toward higher-margin LAL revenue (88% of sales), with the anticipated step-down to 70%-72% for the full year attributed solely to the flow-through of higher-cost 2025 inventory, a temporary headwind expected to normalize as production absorption improves. This inventory-related margin pressure is not indicative of underlying business weakness but rather a transitional factor that will dissipate, allowing gross margin to potentially exceed current guidance ranges in subsequent years as cost structures stabilize and LAL volume growth resumes.
RxSight's commercial reengagement programs, while showing early signs of stabilization in LAL utilization over three consecutive quarters, have not yet penetrated the bulk of its large U.S. installed base of approximately 1,154 LDD units and 2,500 surgeons, with management acknowledging that efforts are still in the "early innings" of reaching through the base. This slow rollout suggests that utilization growth may remain gradual and incremental, falling short of the sequential improvement needed to drive meaningful LAL volume acceleration in 2026, especially given the company's own guidance for only low single-digit LAL growth for the year. The reliance on resource-intensive, in-person workflow support and clinical outcome reviews limits scalability, raising doubts about whether these programs can generate the broad-based adoption lift required to offset the absence of new LDD placements and drive sustainable top-line growth without significant increases in commercial headcount and associated operating expenses.
International expansion, despite recent regulatory approvals in New Zealand, Australia, Europe, and Asia, is explicitly characterized by management as a modest contributor to 2026 revenue, with meaningful impact not expected until 2027 and beyond, contingent on successful commercialization in complex markets like Japan, China, and India, where regulatory cycles are lengthy and commercial adoption remains unproven. The company's reluctance to quantify international revenue contributions—stating it is not yet "material enough to break out"—suggests near-term international sales are likely immaterial, potentially below $5 million, and thus insufficient to offset domestic weakness. This delayed international ramp, combined with the need to build clinical and operational infrastructure from scratch in each market, implies that international revenue will not serve as a near-term growth catalyst, leaving the company overly dependent on a slow-moving domestic reengagement strategy.
Operating expenses are trending toward the high end of the $150 million to $160 million range for 2026, driven by investments in field-facing teams (now 130–150 employees), customer support, education, and R&D, with stock-based compensation alone expected to reach $30 million to $32 million annually. This elevated cost base, coupled with only modest sequential revenue improvement anticipated, raises concerns about the company's path to profitability, especially as gross margin is guided to decline to 70%-72% for the year due to the flow-through of higher-cost 2025 inventory. The combination of rising OpEx and pressured gross margin implies that operating leverage may remain negative or minimal in 2026, with adjusted net loss guidance of $0.19 per share reflecting limited progress toward breakeven, and any delay in utilization growth or international ramp risking further earnings deterioration.
Increasing competition in the premium IOL segment, including new entrants like TECNIS PureSee (J&J), BVI, and Rayner, poses a tangible threat to RxSight's market share, particularly as these competitors offer fixed premium lenses that may appeal to surgeons seeking simpler workflows without the need for postoperative LDD treatments. While management maintains that LAL's adjustability offers superior clinical outcomes, the proliferation of "Me-Too Fixed IOLs" increases competitive noise and could slow adoption among cost- or complexity-sensitive practices, especially if reimbursement pressures continue to favor lower-cost solutions. The lack of specific updates on competitive developments, coupled with reliance on historical advantages like the installed base and clinical knowledge, may underestimate the speed at which well-funded competitors could erode RxSight's differentiation, particularly if they introduce adjustable or hybrid technologies of their own in the near term.
RxSight's commercial reengagement programs, while showing early signs of stabilization in LAL utilization over three consecutive quarters, have not yet penetrated the bulk of its large U.S. installed base of approximately 1,154 LDD units and 2,500 surgeons, with management acknowledging that efforts are still in the "early innings" of reaching through the base. This slow rollout suggests that utilization growth may remain gradual and incremental, falling short of the sequential improvement needed to drive meaningful LAL volume acceleration in 2026, especially given the company's own guidance for only low single-digit LAL growth for the year. The reliance on resource-intensive, in-person workflow support and clinical outcome reviews limits scalability, raising doubts about whether these programs can generate the broad-based adoption lift required to offset the absence of new LDD placements and drive sustainable top-line growth without significant increases in commercial headcount and associated operating expenses.
International expansion, despite recent regulatory approvals in New Zealand, Australia, Europe, and Asia, is explicitly characterized by management as a modest contributor to 2026 revenue, with meaningful impact not expected until 2027 and beyond, contingent on successful commercialization in complex markets like Japan, China, and India, where regulatory cycles are lengthy and commercial adoption remains unproven. The company's reluctance to quantify international revenue contributions—stating it is not yet "material enough to break out"—suggests near-term international sales are likely immaterial, potentially below $5 million, and thus insufficient to offset domestic weakness. This delayed international ramp, combined with the need to build clinical and operational infrastructure from scratch in each market, implies that international revenue will not serve as a near-term growth catalyst, leaving the company overly dependent on a slow-moving domestic reengagement strategy.
Operating expenses are trending toward the high end of the $150 million to $160 million range for 2026, driven by investments in field-facing teams (now 130–150 employees), customer support, education, and R&D, with stock-based compensation alone expected to reach $30 million to $32 million annually. This elevated cost base, coupled with only modest sequential revenue improvement anticipated, raises concerns about the company's path to profitability, especially as gross margin is guided to decline to 70%-72% for the year due to the flow-through of higher-cost 2025 inventory. The combination of rising OpEx and pressured gross margin implies that operating leverage may remain negative or minimal in 2026, with adjusted net loss guidance of $0.19 per share reflecting limited progress toward breakeven, and any delay in utilization growth or international ramp risking further earnings deterioration.
Increasing competition in the premium IOL segment, including new entrants like TECNIS PureSee (J&J), BVI, and Rayner, poses a tangible threat to RxSight's market share, particularly as these competitors offer fixed premium lenses that may appeal to surgeons seeking simpler workflows without the need for postoperative LDD treatments. While management maintains that LAL's adjustability offers superior clinical outcomes, the proliferation of "Me-Too Fixed IOLs" increases competitive noise and could slow adoption among cost- or complexity-sensitive practices, especially if reimbursement pressures continue to favor lower-cost solutions. The lack of specific updates on competitive developments, coupled with reliance on historical advantages like the installed base and clinical knowledge, may underestimate the speed at which well-funded competitors could erode RxSight's differentiation, particularly if they introduce adjustable or hybrid technologies of their own in the near term.